ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of SEBI (LODR) Regulations, 2015, the Company is intimating the request received relating to Loss of share certificate and issue of duplicate share certificate as per attached details. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to the Regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we hereby inform you that a one-on-one meeting is scheduled to be held with analysts/investment managers, as per the details attached. Oxford COVID-19 vaccine: Still aiming for it by year-end, says AstraZeneca CEO
AstraZeneca CEO Pascal Soriot said that the decision to resume the coronavirus vaccine trials rests with a group of independent experts are working to understand if the volunteer's condition was coincidental or a result of the inoculation AstraZeneca's pause on Covid-19 vaccine trial a 'wake-up call', says WHO
"This is a wake-up call to recognise that there are ups and downs in clinical development and that we have to be prepared," Soumya Swaminathan told a virtual briefing from Geneva
China covid vaccine frontrunner says shots are safe amid AstraZeneca setback
Hundreds of thousands of people have received the Covid-19 shots so far, the vaccine developer says.CNBG's two shots are among a handful of the world's fastest-moving coronavirus vaccine candidates now in the final stage of testing
Serum Institute says India trials of COVID-19 vaccine ongoing
AstraZeneca said it has paused global trials, including large late-stage trials, of its experimental coronavirus vaccine due to an unexplained illness in a study participant. Pause in AstraZeneca-Oxford vaccine trial not a setback: UK
Health Secretary Matt Hancock says move won't impact covid vaccine efforts ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Dividend Updates
We refer to our letter dated August 10, 2020 wherein the Company had informed that the Interim Dividend declared by the Board of Directors at their meeting held on August 10, 2020 shall be paid on or before September 8, 2020. In this regard, we confirm that the Company has completed dispatch of interim dividends through electronic mode to all those shareholders whose bank accounts were registered with the Company / Depositories. However, with regard to those shareholder whose bank account details are not registered, the physical instruments for the dividends are being dispatched to their registered address. In view of the current COVID-19 pandemic situation, the physical dispatches is taking a slightly longer time than usual. The Company is making best efforts to ensure that that the physical instruments/ DDs are dispatched within best possible timelines. AstraZeneca Pharma hits fresh record high of Rs 4,489; stock surges 15%
The stock of the company was trading higher for the fifth straight day, surging 26 per cent during the period. AstraZeneca's COVID-19 vaccine enters human trials in Japan
Phase one and two tests are done on small groups of people to see whether the COVID-19 vaccine provokes the immune system and if there are any side effects